Research Analysts Issue Forecasts for BPMC FY2027 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Blueprint Medicines in a research report issued on Wednesday, March 5th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will earn $3.20 per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($1.28) per share.

A number of other brokerages have also recently issued reports on BPMC. JMP Securities reiterated a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Scotiabank assumed coverage on shares of Blueprint Medicines in a report on Friday. They set a “sector outperform” rating and a $150.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. JPMorgan Chase & Co. increased their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler lifted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines currently has an average rating of “Moderate Buy” and a consensus price target of $125.21.

Blueprint Medicines Stock Down 1.6 %

Shares of NASDAQ BPMC opened at $87.12 on Thursday. The firm has a fifty day moving average of $99.43 and a 200-day moving average of $94.27. Blueprint Medicines has a 52-week low of $80.68 and a 52-week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $5.57 billion, a PE ratio of -80.67 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Torray Investment Partners LLC lifted its holdings in Blueprint Medicines by 1.1% in the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock valued at $1,439,000 after acquiring an additional 186 shares during the last quarter. Sherbrooke Park Advisers LLC increased its holdings in shares of Blueprint Medicines by 8.4% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 3,374 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 261 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after acquiring an additional 265 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Blueprint Medicines by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company’s stock worth $580,000 after acquiring an additional 283 shares in the last quarter. Finally, Pitcairn Co. grew its holdings in shares of Blueprint Medicines by 2.8% in the 4th quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company’s stock worth $925,000 after acquiring an additional 293 shares during the last quarter.

Insider Transactions at Blueprint Medicines

In other news, insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the sale, the insider now owns 14,967 shares of the company’s stock, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the transaction, the director now directly owns 152,396 shares of the company’s stock, valued at approximately $16,691,933.88. The trade was a 9.05 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,427 shares of company stock worth $4,837,801. 4.21% of the stock is currently owned by company insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.